Head-to-head evidence
Iloprost vs Treprostinil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Hypertension pipeline
Iloprost · Ventavis
Marketed by Johnson & Johnson and partners
NCT01469169 · Phase 3 · completed
This was a small, single-group, open-label study with no randomized control or comparator arm, and its primary efficacy measure—change in pulmonary vascular resistance—was a hemodynamic surrogate rather than a direct clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Treprostinil · Orenitram / Remodulin / Tyvaso
Marketed by United Therapeutics and partners
NCT00325403 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 349 participants enrolled and 228 included in the prespecified primary analysis. The clinical primary endpoint was met: oral treprostinil produced a statistically significant placebo-corrected improvement in six-minute walk distance at Week 12.
Next expected readout: May 2027 · NCT07759804 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloprost's landscape · Treprostinil's landscape